Stapled Peptides Inhibit KRAS-Raf Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cancers involving KRAS mutations, such as those in Ras family members like KRAS, are limited in specificity and effectiveness due to the challenges in inhibiting the Kras/Raf interaction, which is crucial for tumor growth and metastasis.
Innovation Solution
Development of stapled peptides based on the helical domain of Raf RBD, specifically designed to inhibit the binding of mutant Kras to GST-RBD, offering a targeted approach to disrupt this interaction and potentially halt tumor progression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for cancers involving KRAS mutations, then treatment coverage is broad, but specificity and effectiveness are limited
Solution Approach 1:
The patent uses stapled peptides as intermediary molecules that specifically bind to the Ras-binding domain (RBD) of Raf-1, blocking the interaction between mutant KRAS and Raf-1. This mediator approach allows selective inhibition of the Kras/Raf interaction without affecting other pathways, thereby improving both effectiveness and specificity simultaneously
Solution Approach 2:
The stapled peptides are designed to target a specific local region (the Ras-binding domain of Raf-1) rather than acting globally. By modifying specific amino acid residues and introducing staples at particular positions, the peptide achieves high local specificity for the mutant Kras/Raf interface while maintaining stability and activity
2Reliability
If stapled peptides are designed to inhibit Kras/Raf interaction, then binding inhibition is achieved, but structural complexity increases
Solution Approach 1:
The Raf-1 Ras-binding domain is segmented into critical regions, with the stapled peptide targeting a specific segment (residues 78-92 corresponding to the helical domain). By focusing on a segmented portion rather than the entire protein-protein interface, the peptide achieves effective inhibition with reduced structural complexity compared to full-length inhibitors
Solution Approach 2:
The patent modifies physical and chemical parameters of the peptide by introducing staples (cyclic constraints) at specific positions, changing the conformational flexibility and stability parameters. This allows the peptide to maintain a stable active conformation that effectively binds to the target, achieving high binding inhibition without requiring excessive structural complexity
Data Source
AI summary
Stapled peptides and methods of using them to inhibit the Kras/Raf interaction are disclosed herein.